Novo Nordisk reported strong first-quarter results driven by Wegovy and Ozempic, with sales up 24% and pre-tax profit up 29%, and raised its full-year profit forecast to £15.3 billion.
Novo Nordisk reported a strong financial performance at the start of 2024, driven by rampant demand for weight-loss and diabetes drugs Wegovy and Ozempic.
The company said its first-quarter sales were up 24% and pre-tax profit was up 29%.
The company highlighted that it is adding around 27,000 new Wegovy patients each week in the United States.
Looking to the rest of the year, the company upgraded its forecast for full-year profit to £15.3 billion.
Novo Nordisk is presently the most valuable company in Europe.
Explore Bias
Financial media reports emphasize Novo Nordisk’s apparent financial health and growing wealth.
Some outlets highlight somewhat sensationalist celebrity connections and endorsements, which have been fuelling the popularity of weight loss drugs.
Explore More Stories
- "Blockbuster Obesity Drug Demand Drives Novo Nordisk Profit Boost" - MSN / Reuters
- "Novo Nordisk: Wegovy, Ozempic Prices in US Fell in Q1" - Investing.com
- "Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy" - Forbes
- "Danish Firm Behind Weight-Loss Drug Wegovy Raises Profit Forecast to £15.3bn" - The Guardian
- "Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double" - CNBC
- "Growing demand for weight-loss drugs fattens Novo Nordisk profits" - The Times
